BRAXX focuses on developing novel radiation treatment solution for cancers. BRAXX designs new generation of brachytherapy applicator for esophageal cancer according to clinical needs; this applicator gives clinicians and radiologists a better tool deliver therapy.
In conventional brachytherapy to treat esophageal cancer using radiation, the radiation is not only delivered to tumor cells, but healthy tissues are also exposed. This usually causes unfavored local control rate and other side effects. We designed an applicator that contains multiple balloons that each allows independent control to achieve precision positioning and targeting.
By adjusting individual balloons, radioactive source can be placed at desired position based on computed tomography. The applicator can be positioned according to tumor size and location. This method can increase the conformity of radioactive treatment and greatly decrease side effects due to exposure of radiation to normal tissue.
Based on preliminary physical studies, it is found that our designed applicator can reduce the amount of radiation exposed to as much as 60% comparing to using regular nasogastric tube. It is expected that this technology will provide esophageal and other cancer patients a better treatment plan.
BRAXX applicator is a patented technology. The applicator received FDA 510(k) clearance, and expected to obtain TFDA approval in 2019 Q3.
Cooperation projects and needs
1. Request Oversea Distributor
2. Request Business partner